Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > It's over the Judgement has been released

<< Previous

Bullboard Posts

Next >>

Post by Ingiboyon Oct 16, 2023 8:21pm

262 Views

Post# 35686396

It's over the Judgement has been released

2023-10-16 19:09 ET - News Release

Mr. Andrew Schutte reports

REPLICEL LIFE SCIENCES ANNOUNCES ARBITRATION DECISION

On Monday, Oct. 16, 2023, RepliCel Life Sciences Inc. received the final award related to its continuing arbitration proceedings with Shiseido Co. Ltd. The tribunal dismissed RepliCel's claims finding that Shiseido validly terminated the collaboration and technology transfer agreement dated effective as of July 9,

2013. Management is currently considering the impact of the decision and
assessing its options.